Abcam Plc (LON:ABC)‘s stock had its “hold” rating reaffirmed by Peel Hunt in a research note issued to investors on Tuesday. They currently have a GBX 1,020 ($13.46) target price on the stock. Peel Hunt’s price objective points to a potential upside of 2.51% from the stock’s previous close.
A number of other research firms also recently weighed in on ABC. Berenberg Bank reaffirmed a “buy” rating and issued a GBX 1,100 ($14.52) target price on shares of Abcam Plc in a research report on Monday, September 11th. Panmure Gordon reaffirmed a “sell” rating on shares of Abcam Plc in a research report on Thursday, July 27th. Numis Securities Ltd reaffirmed an “add” rating and issued a GBX 1,116 ($14.73) target price on shares of Abcam Plc in a research report on Thursday, July 27th. Finally, J P Morgan Chase & Co reaffirmed a “neutral” rating and issued a GBX 864 ($11.40) target price on shares of Abcam Plc in a research report on Tuesday, September 12th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and one has issued a buy rating to the company’s stock. Abcam Plc presently has a consensus rating of “Hold” and an average price target of GBX 972.67 ($12.84).
In other news, insider Jonathan Simon Milner sold 567,033 shares of Abcam Plc stock in a transaction dated Thursday, September 21st. The shares were sold at an average price of GBX 1,017 ($13.42), for a total value of £5,766,725.61 ($7,609,825.30). Also, insider Louise Patten acquired 1,636 shares of the firm’s stock in a transaction dated Thursday, September 14th. The stock was purchased at an average cost of GBX 1,079 ($14.24) per share, with a total value of £17,652.44 ($23,294.33).
About Abcam Plc
Abcam plc is a global life sciences company. As a developer of reagents and tools, the Company’s purpose is to serve life science researchers globally. Providing the research and clinical communities with tools and scientific support, the Company offers validated biological binders and assays to address important targets in critical biological pathways.
Receive News & Ratings for Abcam Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam Plc and related companies with MarketBeat.com's FREE daily email newsletter.